Formulation: A solid
Formal Name: 4-((1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one-3,5,5-d3
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C29H41D3O12
Formula Weight: 587,7
Shelf life (days): 1460
Notes: Ouabain-d3 is intended for use as an internal standard for the quantification of ouabain by GC- or LC-MS. Ouabain is a cardiac glycoside that has been found in S. gratus and has diverse biological activities.{72165,65175,52442,63309,72166,13089,65170} It inhibits the Na+/K+-ATPase isoforms α1β1 and α2β1 and human-ether-a-go-go (hERG), also known as Kv11.1 (IC50s = 97, 90, and 15.2 nM, respectively).{65175,52442} Ouabain reduces the proliferation of PC3 prostate cancer and U937 lymphoma cells (EC50s = 210 and 94 nM, respectively).{63309} It inhibits the cytopathic effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in infected Vero cells (IC50 = in vivo.{65170} Formulations containing ouabain have been used in the treatment of atrial fibrillation, atrial flutter, and heart failure.
English
Deutsch
